Results Presentation 2026
Released
Released
Announcement PDF
FY26 Results Presentation
ASX Release
20th August 2026
ASX:TTX
Tetratherix Limited 2026 Anchored by Science
Tetratherix Limited (ASX:TTX) (Tetratherix) is pleased to announce its FY26 financial results
presentation.
A copy of the CEO letter contained in the Annual Report lodged with ASX on 20 August 2026 is also
available on Medium.
< ENDS >
InvestorHub
The Tetratherix InvestorHub platform provides existing and prospective shareholders with
real‑time access to ASX announcements, reports and presentations. You can visit the Tetratherix
Investor Hub at:
Authorised for release by the CEO.
For further information contact:
Jacob Pfeffer
General Counsel | Chief of Staff | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
Tetratherix Limited 2026
Tetratherix
FY26 Results Briefing
Anchored by Science
FY26 Results Investor Overview
USE OF THIS DOCUMENT
You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any
modifications to them, and make or give the acknowledgements, representations or warranties (as applicable). This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended
to be relied upon as advice to investors or other persons. The information contained in this presentation was prepared by Tetratherix Limited ACN 607 771 077 (Tetratherix) as of its date, and remains subject to change without notice. This presentation has been provided to you solely
for the purpose of giving you background information about Tetratherix.
DISTRIBUTION OUTSIDE AUSTRALIA
The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate
applicable securities law.
FORWARD-LOOKING STATEMENTS
This presentation may include forward looking statements. Such statements can generally be identified by the use of words such as 'may', 'will', 'expect', 'intend’, 'plan', 'estimate', 'anticipate', 'believe', 'continue', 'objectives', 'outlook', 'guidance‘, ‘forecast’ and similar expressions.
Indications of plans, strategies, management objectives, revenue and financial performance are also forward-looking statements. Such statements are not guarantees of future performance, and involve known and unknown risks, uncertainties, significant items of subjective
judgement, assumptions (including in relation to future events that may or may not eventuate), contingencies and other factors, many of which are outside the control of Tetratherix. No independent third party has reviewed the reasonableness of any such statements or
assumptions. No representation is made or will be made that any forward-looking statements will be achieved or will prove to be correct. Actual results, performance, operations or achievements may vary materially from any forward-looking statements. Circumstances may
change and the contents of this presentation may become outdated as a result. Readers are cautioned not to place undue reliance on forward looking statements. Except as required by law, Tetratherix assumes no obligation to release updates or revisions to forward looking
statements to reflect any changes. You should form your own views as to these matters and any assumptions on which such statements are based and not place reliance on such statements. No representation or warranty, expressed or implied, is made as to the accuracy, reliability,
adequacy or completeness of the information contained in this presentation. To the maximum extent permitted by law, Tetratherix excludes and disclaims all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred
either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation.
PAST PERFORMANCE AND RISKS
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. An investment in Tetratherix is subject to known and unknown risks, some of which are beyond the control
of Tetratherix, including factors and risks specific to the industry in which it operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Tetratherix does not guarantee any particular rate of return on its
performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations
and the impact that different future outcomes may have on Tetratherix.
NO OFFER, INVITATION OR ADVICE
This presentation is not, and is not intended to constitute, financial advice, or an offer or an invitation, solicitation or recommendation to acquire or sell Tetratherix shares or any other financial products in any jurisdiction and is not a prospectus, product disclosure statement,
disclosure document or other offering document under Australian law or any other law. This presentation does not form the basis of any contract or commitment to sell or apply for securities in Tetratherix or any of its subsidiaries. It is for information purposes only. Tetratherix does
not warrant or represent that the information in this presentation is free from errors, omissions or misrepresentations or is suitable for your intended use. The information contained in this presentation has been prepared without taking account of any person’s investment objectives,
financial situation or particular needs and nothing contained in this presentation constitutes investment, legal, tax or other advice. The information provided in this presentation may not be suitable for your specific needs and should not be relied upon by you in substitution of you
obtaining independent advice. Subject to any terms implied by law and which cannot be excluded, Tetratherix accepts no responsibility for any loss, damage, cost or expense (whether direct, or indirect, consequential, exceptional or special damages including but not limited to loss
of revenue, profits, time, goodwill, data, anticipated savings, opportunity, business reputation, future reputation, production or profit, any delay costs, economic loss or damage) incurred by you as a result of any error, omission or misrepresentation in this presentation.
UNAUDITED INFORMATION
All forward-looking figures and proforma statements in this presentation are unaudited. Certain figures may be subject to rounding differences. All market share information in this presentation is based on management estimates having regard to internally available information
unless otherwise stated.
PRESENTATION OF INFORMATION
All currency amounts in this presentation are in Australian dollars unless otherwise stated.
IMPORTANT INFORMATION & DISCLAIMER
Who is Tetratherix?
Anchored by Science
FY26 Results Investor Overview
The Tetratherix Mission
Our goal is to derive products from our platform technology to expand healthcare access by treating more patients
outside traditional hospital and surgical settings, fostering greater health equity worldwide and improving clinical
outcomes.
We use the modularity of the Tetramatrix™ platform to partner with key market leaders to develop new technologies
and together maximise impact.
We will treat 10 million patients by 2035 by using our platform technology.
We are an Australian biomedical technology company, founded in 2015 as an advanced manufacturing and
intellectual property-generating entity in the biomaterial and regenerative medicine space. At our core, we have our
flagship Tetramatrix™ platform technology.
We commercialise multiple products derived from our Tetramatrix™ platform technology through a flywheel model
in which our established foundational intellectual property, safety, efficacy, and streamlined manufacturing
processes facilitate the rapid and efficient development of products in different fields of medicine.
We have been building this company and its platform technology for 15 years, having started the journey as a PhD
thesis at the University of Sydney. The founders and inventors of the technology continue to control and drive the
company towards its mission.
Tetramatrix™ is a biostealth fluid technology
engineered to transition at physiological
temperature and form a tissue-adhering 3D matrix
after delivery. Designed as a single platform it can
be adapted to distinct derivatives for different
tissues, indications and delivery requirements
without reinventing the underlying system each
time.
Our Tetramatrix™ Platform Technology
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
ISO 13485
Certification
Ralph Street Lab
Built
First Institutional
Funding
IPO
Platform
Validated
Precision
Medicine Launch
First 50 patients
treated
First Global
Partnership
Anchored by Science
TTX Timeline - 15 Years in the Making
FY26 Results Investor Overview
FDA 510k
Complete
2015 2030
First Patent
Granted
First Clinical
Trial
Impact
Commercialisation
2026
Commercial
Launch of the
TTX Platform
WE ARE
HERE
Fifteen years of deliberate work sit behind the
milestone stack. Every step was sequenced so it
would build on the one before, carrying us
steadily from early science towards commercial
scale. The structure moves us into
commercialisation and the generational patient
impact we set out to create.
The TTX Decade
Development Arc
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Our first generation of products are
launching into global markets in 2026,
representing an exciting inflection point in
the TTX journey.
Anchored by Science
FY26 Results Investor Overview
TTX by the numbers
Active Product Programs
0 20 40 60 80 100
Bone Regeneration
Tissue Spacing
Tissue Healing
Precision Medicine
Bone Regeneration
Tissue Spacing
Precision Medicine
Tissue Healing
Proof of Concept Pre-Clinical Clinical Regulatory
MARKET
LAUNCH
Products being developed
from a single technology in
the first generation
6
3X
Enhanced productivity
With flywheel in motion
from experience and AI/
digitalisation
15
Years of deep R&D on the
cusp of changing lives around
the world
03
New chemistries with
95% similarities from
our single Tetramatrix
Platform technology
Global R&D Infrastructure
10
Years being
ISO:13485 Certified
12
Independent
Research
Organisations
42
Granted Patents
2044
Patent Expiry Timeframe
Digital
Internal Machine Learning Tool*
*: Embedded internal digital tool to enable effective discovery of new and ongoing opportunities
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
The Tetramatrix™
Platform Technology
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Tetratherix Limited 2026
01. Rising Patient Expectations
Patients are increasingly expecting higher quality of care with a particular
focus on reducing recovery times and the lower risk of complications -
which is also a driver of increasing healthcare costs for patients and payers
globally.
02. Need for Cost-Effective and Decentralised Care
Increasing global healthcare spending and demand for healthcare services
are necessitating investment in cost-effective tools and treatments,
including those that can be delivered outside a traditional hospital setting,
to minimise burden on the healthcare system.
03. Easier Healthcare Delivered Wherever Care Happens
Consumers are taking a bigger role in healthcare choices, they are
demanding safer, easier options they can use at home or assisted in
outpatient settings focused on predictable performance that improves
access and outcomes.
Anchored by Science
The Evolving Dynamics of Global Healthcare Demand Innovative & Cost-Effective Biomaterials
FY26 Results Investor Overview
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
Tetramatrix™ Platform Technology
FY26 Results Investor Overview
Our Tetramatrix platform is best positioned to address the clinical demands that are central to the evolution
01
Water-based solution
that can be injected or
sprayed into the body
without causing
disruption to the
surrounding host tissue.
Universal
Minimally
invasive delivery
02
Engineered for
predictable point-of-
care handling without
bespoke infrastructure,
with controlled transition
at physiological
temperature for
repeatable, measurable
and clinically practical
performance.
Seamlessly
integrates into
existing workflow
03
With seamless
biocompatibility,
Tetramatrix™ works
with the body then
disappears with no
fuss, no noise and
nothing left behind.
Biostealth:
Engineered to be
ignored
04
Built with
manufacturability,
robust quality systems
and scalability in mind,
Tetramatrix™ supports
clear pathways from
development through to
validation and ultimately
real-world clinical
deployment.
Manufactured at
low cost and
scaled
Tetramatrix
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
Tetramatrix™ Platform Technology
01
The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by
physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue.
Intelligent
02
A biomaterial platform built with unique polymer programming akin to ‘medical Lego®’ to form implantable products
to solve a wide range of clinical problems.
Modular
03
The matrix has similar water content and mechanical properties to natural tissue, and therefore is impervious to the body,
bridging healthy and injured tissues, helping heal injuries or physically manipulating the body during surgical interventions.
Biomimetic
Tetramatrix™ is a synthetic material supplied in a ready-to-use syringe
format that fits within the existing clinical workflow rather than changing
it. It is manufactured locally, at scale and at low cost.
Tetramatrix
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
The Tetramatrix™ platform is applied
across four distinct clinical use cases we
call franchises. In practice, we do what a
material can usefully do inside the body: we
help repair both soft and hard tissue, we
deliver therapeutics, and we create and
hold surgical space. Our products are
developed to go deeper within each
application rather than broader across
many, so that every derivative is refined for
the clinical problem it solves.
Bone Regeneration Tissue Healing
Bone Regeneration products on the
Tetramatrix™ platform are flowable
bone extenders for dental and
orthopaedic defects where
placement and retention matter.
They set into a tissue-conductive
matrix that host cells grow through,
integrating biologically.
Tissue Healing products on the
Tetramatrix™ platform integrate
physically and biologically with soft
tissue anywhere in the body, forming
a synthetic, inert bridge channelling
new tissue in. Clinically explored for
incisional scar prevention, with
potential in spine, cartilage and
tendon.
Tissue Spacing Precision Medicine
Tissue Spacing products on the
Tetramatrix™ platform create and
maintain surgical space, injected
simply and visible under multiple
conditions. Their stability,
resorption and modularity span
needs from radiation therapy to
cataract microsurgery.
STEPP, our first Precision Medicine
product, is a sprayable Tetramatrix™
system for intranasal delivery —
clinically reproducible, minimally
invasive, easy to use. It protects the
compound, forms an adhesive nasal
cushion and speeds bloodstream
uptake.
Tetramatrix™ Clinical Franchises built on a single platform
1 2
3 4
A. Same Technology
B. Multiple Opportunities
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Tetratherix Limited 2026
Tetramatrix™
Product Portfolio
Generation 1
Our Generation 1 products are the
first commercial derivatives of the
Tetramatrix™ platform, each
engineered from the same core
chemistry for a specific clinical need.
They span all four franchises:
Tegenix and TegenEOS for bone
regeneration, Tutelix and Optimatrix
for tissue spacing, TetraDerm for
tissue healing, and STEPP for
precision medicine. Together they
show how a single platform
technology can be programmed into
distinct, purpose-built products
across a broad range of surgical and
therapeutic settings.
Tegenix
Bone
Regeneration
Tissue
Spacing
Tissue
Healing
Precision
Medicine
TegenEOS
Tutelix
Optimatrix
TetraDerm STEPP
Anchored by Science
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Tetratherix Limited 2026
FY26 Results
& Highlights
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
Avoided Sales &
Marketing Cost by
using partners’ in-
market
infrastructure
Design
Proof of
Concept
Clinical
Validation
Regulatory
Approval
Go-to-
Market
Income
Cost
Plateaued
Cost In TTX
Model
FY26 Financial Highlights
A capital light model with compounding revenue
This business was built lean from the outset, not reshaped into it during FY26.
We don't carry the cost of owning commercialisation, regulatory filings or
market access in every territory; our partners do, and they're better resourced
to do it than we ever would be. What we hold onto is the part of the value chain
that scales without adding cost: a single Tetramatrix™ chemistry, licensed and
supplied into every derivative product the platform can support. That's why our
licence and supply revenue runs at a gross margin most product companies
can't match, and why it gets more profitable as it grows rather than just bigger
— each new partner adds revenue on essentially the same fixed cost base,
without a new commercial team or regulatory function built to support them.
This unique and attractive model is enabled by:
A platform technology that allows parallel developments
Advanced manufacturing with economies of scale
Partnerships with leading players who are motivated to sell over a long time
A patient & deliberate strategy
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Supply of
product at
scale
Licensing &
Milestone
Payments
1 2
Anchored by Science
FY26 Results Investor Overview
FY26 Financial Highlights
Cashflow: $15.6m (before costs) from May 2026 placement plus $4.2m Superpower Licence Revenue has funded incremental
growth over and above the IPO strategic plan
$20.5 million (87%) of cash inflows are incremental to the Prospectus
assumptions and will be used to expedite manufacturing expansion
and investment in digital and customer success
R&D investment $5.1 million, 31% of total cash outflows driven
by Bone Regeneration progress towards FDA 510(k) clearance
and the Precision Medicine addition to the portfolio in FY26
1 2
$13.6m
Financing
cashflow
Licence Revenue
$4.2m
IGP $1.6m
Net cash from /
(used in) operating
activities
Opening cash and
cash equivalents
1 July 25
Closing cash and
cash equivalents
30 June 26
Net cash from /
(used in) financing
activities
$29.3m
($5.6m)
($4.8m)
R&D incentive $1.5m
Supplier payments
Employee payments
Property, plant and
equipment
$(4.4m)
Net cash from /
(used in) investing
activities
$34.4m
Outflows Inflows Balance
Offer costs $(0.4m)
($2.3m)
Operating
cashflow
($6.4m)
Investing
cashflow
Investments ($0.8m)
Intangibles ($1.1m)
Net proceeds
from issue of
securities
$14.7m
Lease liabilities ($0.7m)
Interest income $0.8m
AUD
$ million
Incremental inflow to prospectus
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Operational Highlights
FY26 Results Investor Overview
Changing the way drugs are delivered
on the back of 5+ years of mRNA
delivery research. Tetratherix has now
launched its drug delivery franchise,
targeting the exciting intersection of
consumer preventative medicine and
metabolic health.
01
Patient impact is how we
measure our success.
Tetramatrix™ platform
technology has now been used
across multiple clinical trials with
over 75 patients included. This
number will significantly grow
upon market clearance in 2026.
58% Growth in
Patient Impact
2026 Highlights
Growing patient impact, anchored by
science. Working closely with our
development partners, TTX has
progressed the clinical safety &
efficacy testing for its pipeline
products in scar prevention, urological
spacing and cataract surgeries.
02
Reaching the commercial
inflection point. Tetratherix is
now officially a revenue
generating business, having
successfully transitioned from
an R&D house to a commercial
entity.
First Revenues
of $4.2m*
03
Significant regulatory milestone met.
2026 saw TTX complete its first full
FDA dossiers including performance
and safety testing for our dental and
orthopaedic bone regeneration
products for initial market launch in
the US.
Completed First
FDA Submission
04
Federal Government support for
Australian Export. With the support of
a $3.3m IGP grant, we have now
begun the build of our bespoke
advanced manufacturing facility to
increase our capabilities by 10x in
Sydney, Australia with completion
estimated to be in late 2026.
Production
Readiness
Underway
05
Precision
Medicine Launch
06
Paving the Path
with our Pipeline
*The $4.2 million licence revenue is being recognised on a straight-line basis over the 12-month period from April 2026. Of this, $0.9 million has
been recognised in the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Operational Highlights
FY26 Results Investor Overview
58% Growth in Patient Impact
Patient impact is how we measure our success. The
Tetramatrix™ platform has now been used across multiple
clinical trials, with more than 75 patients treated to date, and
that number is set to grow considerably once we reach market
clearance in 2026.
Across the year the TetraDerm clinical trial advanced into
cohorts 2 and 3, with major wounds now being treated and with
strong indications of performance in reducing scar formation.
The Tutelix pilot trial was completed with 15 patients treated,
recording no adverse events to date, outstanding clinical
usability outcome and space generating capability. Human
Research Ethics Committee approval was granted for the
Tutelix pivotal trial towards the product clearance with the FDA.
01
Patient Impact
Score FY26
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
A. Tutelix First In Human Success
The first in human (FIH) clinical trial for Tutelix product was
initiated and all planned 15 patients completed their treatment
with no product related adverse event. The product
administration was successfully completed for all patients across
two sites in Australia. The visibility of the product once injected
provided a safe and easy to use product for the clinicians while
the mechanical performance of the forming hydrogel and its “lift”
strength formed an homogeneous space anatomically between
prostate and other tissues.
Tutelix Clinical
Performance
Confirmed
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
A. Tutelix First In Human Success
After injection (t=0) After Three Months After Six Months
Product displayed an outstanding structural stability at the injection
site for 3 months. MRI results displayed “water intake” at this time point
which is a prerequisite for over time hydrolysis and resorption of the
injected structure. The uniformity of the structure and its stability for at
least 3 months can provide solid basis to expand the application of the
technology for pelvic cancer.
Tutelix stability
results unlock
Expansion of the
Oncology Spacing
opportunity
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
B. TetraDerm Clinical Trial Progress
TetraDerm Clinical Trial progressed in two sites in Australia. The
results from the unblinded cohort 1 showed strong indications of
efficacy for the technology to reduce scar formation. No report of
inflammation, seroma formation and no report of hypertrophic
scarring are all aligned with the expected mode of action for
TetraDerm.
Operation 1 Week 6 Weeks
6 Months 12 Months
Cohort 2 recruitment with
18 patients completed and
significant progress has
been achieved in cohort 3
that involves up to 1.5 m
wounds after breast
augmentation, belt
lipectomy and other major
surgeries.
70
Oldest patient
treated in the trial
with VSS of <1 at
all time points
years of age
9
Relatively large
wounds with no
healing issues
observed
cm wound length
0
No reports of
seroma formation
in any of the
treated wounds
seroma formation
ZERO
No reports of
inflammation from 2
weeks onwards in
any of the patients
inflammation
TetraDerm Opportunity
Validated
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Operational Highlights
FY26 Results Investor Overview
First Revenues of $4.2m*
Reaching the commercial inflection point. Tetratherix is now
a revenue-generating business, having made the transition
from an R&D house to a commercial entity.
This first revenue is an annual licensing fee that gives a
single partner access to our intellectual property, and it
establishes a model we can extend as further partners are
added across the entire platform. Supply of the
Tetramatrix™ platform polymer will build on this base,
adding a second stream to our revenue-generating
potential.
02
*The $4.2 million licence revenue is being recognised on a straight-line basis over
the 12-month period from April 2026. Of this, $0.9 million has been recognised in
the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.
$4.2m in revenues
from Tetramatrix™
commenced in
2026
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Operational Highlights
FY26 Results Investor Overview
Completed First FDA Submissions
A significant regulatory milestone met. In 2026 Tetratherix
completed its first full FDA dossiers, covering the
performance and safety testing for our dental and
orthopaedic bone regeneration products ahead of their
initial market launch in the United States.
The submissions were completed on the back of multiple
pre-submission meetings with the FDA and draw on 27
internal reports, the full suite of ISO 10993 preclinical safety
studies, and two large-animal performance studies.
Completing this work sets the regulatory flywheel in motion
and makes each future submission easier to prepare. It is a
licence to hunt and the beginning of a longer journey.
03
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
FDA submission Data Read out
As a novel platform material, and to enable effective and efficient
motion of our flywheel for our current and future FDA
submissions, we went above and beyond to confirm the safety of
our polymer platform per ISO10993. An independent review of
data with a biological safety scientist and a principal toxicologist
in the US concluded that the platform is safe, based on a weight-
of-evidence assessment from numerous in vivo studies, and
demonstrated no evidence of irritation, sensitisation, systemic
toxicity, genotoxicity, pyrogenicity or carcinogenicity from the
platform.
Tegenix Excels in FDA
Performance Study
Week 8 Week 12
0
5
10
15
20
25
30
35
Total
Bone
Volume
(mm
)
Control Tegenix Control Tegenix
3
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
FDA submission Data Read out
The sites were integrated with the host tissue,
and the Tegenix treated sites demonstrated
the product’s proposition, allowing bone
ingrowth within the grafted site, leading to
greater bone volume.
Greater Volume
of Bone with
Tegenix vs
predicate
Tegenix site Control site
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
FDA submission Data Read out
The results from these clinically relevant models confirmed
that Tegenix: (a) acts as an effective carrier for any type of
bone grafts (animal or human-derived) to enhance their
usability and handling; (b) supports natural healing with no
inflammatory/ foreign body reaction to Tegenix; and (c)
provides a 3D matrix to hold them in place to enable cellular
ingrowth and activation. The impact was more evident where
adhesivity of Tegenix matrix plays an important role (for
example in upper jaw).
Tegenix Mechanism
of Action Confirmed
Company Overview FY26 Results & Highlights FY27 Opportunity Ahead
Platform Overview
Anchored by Science
FY26 Results Investor Overview
FDA submission Data Read out
TegenEOS allows effective delivery of
autografts to the site for effective
integration of the newly formed bone with
the host environment (turquoise blue area
showed the original location of the defect).
TegenEOS
Excels in FDA
Performance
Study
TegenEOS
Company Overview FY
Share your feedback
Discover